Peptides for Boxer cranial cruciate ligament (ccl) tear
The short answer
Boxers carry an elevated predisposition to cranial cruciate ligament (ccl) tear. The compounds investigated for it are BPC-157, TB-500, MGF. At a typical Boxer weight of 25–32 kg (55–71 lb), this breed falls in the medium breed dosing class.
Cranial cruciate ligament (CCL) tear in Boxers
The cranial cruciate ligament is the canine equivalent of the human ACL, and its rupture is the most common orthopaedic injury veterinary surgeons see. Unlike in people, canine CCL disease is usually degenerative rather than traumatic — the ligament frays over months before it fails, which is why so many dogs rupture the second side within a year or two. Surgical stabilisation is the standard of care for most dogs. Peptide research in this context is directed at the recovery phase and at the soft tissue environment, not as an alternative to stabilising an unstable joint.
Dosing at Boxer body weight
Calculated for a 29 kg (64 lb) dog — the midpoint of the typical range for this breed.
| Compound | Dose at 29 kg | Frequency | Evidence |
|---|---|---|---|
| BPC-157 | 58–290 mcg | Once daily | Emerging evidence |
| TB-500 | 2.9–7.25 mg | Loading 1-2x weekly, then half dose weekly | Emerging evidence |
| MGF | 58–145 mcg | Daily or every other day | Preliminary / in vitro only |
Weigh your dog rather than using a breed average — an individual Boxer can sit well outside the typical range. Use the dose calculator for an exact figure.
Common questions
What peptides are used for cranial cruciate ligament (ccl) tear in Boxers?+
BPC-157, TB-500, MGF are investigated for cranial cruciate ligament (ccl) tear. No breed-specific pharmacological restriction is established for Boxers among these compounds.
How much should a Boxer be given?+
Boxers typically weigh 25–32 kg (55–71 lb), placing them in the medium breed class. BPC-157: approximately 58–290 mcg at 29 kg. TB-500: approximately 2.9–7.25 mg at 29 kg. MGF: approximately 58–145 mcg at 29 kg. Weigh your dog rather than relying on a breed average.
Are Boxers more prone to cranial cruciate ligament (ccl) tear?+
Yes. Boxers carry an elevated predisposition to cranial cruciate ligament (ccl) tear. Rupture of the stabilising ligament in the stifle, the single most common orthopaedic injury in dogs.
References
- 1.CANINE STUDYHe L, et al. Pharmacokinetics, distribution, metabolism and excretion of BPC 157 in rats and dogs. Frontiers in Pharmacology, 2022. PMID 36588722
- 2.CANINE STUDYXu C, et al. Preclinical safety evaluation of body protective compound-157. Regulatory Toxicology and Pharmacology, 2020. PMID 32334036
- 3.Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine. Orthopaedic Journal of Sports Medicine, 2025. PMC12313605
- 4.Gwyer D, Wragg NM, Wilson SL Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 2019. PMID 30915550
- 5.Jozwiak M, et al. Multifunctionality of BPC 157: Literature and Patent Review. Pharmaceuticals, 2025. PMC11859134
- 6.CANINE STUDYJournal of the American Holistic Veterinary Medical Association Case report: canine stifle injury managed with BPC-157 and TB-500. JAHVM, 2023. View source
- 7.Kleinman HK, Sosne G Thymosin beta 4 promotes dermal healing: animal studies. Annals of the New York Academy of Sciences, 2010. PMID 20536453
- 8.Goldstein AL, Hannappel E, Sosne G, Kleinman HK Thymosin beta-4: a multi-functional regenerative peptide. Expert Opinion on Biological Therapy, 2012. PMID 22074294
- 9.Kwok WH, et al. Doping control analysis of TB-500 in equine urine and plasma. Journal of Chromatography B, 2013. PMID 23084823
- 10.Esposito S, et al. TB500/TB1000: understanding misbranded drugs. Drug Testing and Analysis, 2022. View source
- 11.Goldspink G Mechanical signals, IGF-I gene splicing, and muscle adaptation. Physiology, 2005. PMID 16174871
Other conditions Boxers are predisposed to: Canine cancer support, IBD and gut health, Skin and coat.
Where to source research peptides
Compound quality is the variable most owners underestimate. Purity, accurate peptide content, and correct labelling determine whether any published dosing figure means anything at all. Pet & Peps Research publishes third-party testing on the compounds covered in this guide and supports this site.
Educational information — not veterinary medical advice
Everything on this page is compiled from published peer-reviewed literature for educational and research purposes. It does not establish a veterinarian-client-patient relationship (VCPR) and is not a substitute for veterinary examination and diagnosis. Most compounds described here are investigational or used off-label and are not FDA-approved for these purposes in dogs. Extralabel drug use in animals requires a valid VCPR and the direct supervision of a licensed veterinarian under AMDUCA (21 U.S.C. §360b). Dosing figures are reported as they appear in the source literature and are not recommendations.